天壇生物(600161.SH):所屬四家漿站獲得單採血漿許可證
格隆匯2月23日丨天壇生物(600161.SH)公佈,公司所屬國藥集團蘭州生物製藥有限公司張家川回族自治縣蘭生單採血漿有限責任公司、靖遠蘭生單採血漿有限責任公司、康縣蘭生單採血漿有限責任公司、民樂縣蘭生單採血漿有限責任公司於近日收到甘肅省衞生健康委員會簽發的《單採血漿許可證》。
公司表示,上述四家漿站自此次取得《單採血漿許可證》之日起可正式採漿。上述漿站實現採漿將有利於提升公司原料血漿供應能力,對公司長期發展具有積極作用。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.